CAT
62
7
CI
52
7
NWL
50
6
FITB
60
2
AKAM
50
7
GOOG
53
-12
KLAC
43
4
GPC
37
2
GM
68
3
GRMN
64
2
MAS
56
5
SBUX
39
3
VRSK
77
4
EQIX
62
2
CVX
44
-2
ROP
59
5
GOOGL
45
-9
ESS
64
4
VTR
54
5
CB
51
3
CAT
62
7
CI
52
7
NWL
50
6
FITB
60
2
AKAM
50
7
GOOG
53
-12
KLAC
43
4
GPC
37
2
GM
68
3
GRMN
64
2
MAS
56
5
SBUX
39
3
VRSK
77
4
EQIX
62
2
CVX
44
-2
ROP
59
5
GOOGL
45
-9
ESS
64
4
VTR
54
5
CB
51
3
Financhill
Back

Fulcrum Therapeutics 10K Form

Sell
41

FULC
Fulcrum Therapeutics

Last Price:
3.25
Seasonality Move:
63.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FULC News And Ratings

See the #1 stock for the next 7 days that we like better than FULC

FULC Financial Statistics

Sales & Book Value

Annual Sales: $2.81M
Cash Flow: $-19.09M
Price / Cash Flow: 0
Annual Sales: $4.77
Price / Book: 0.68

Profitability

EPS (TTM): -0.31000
Net Income (TTM): $-17.91M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Fulcrum Therapeutics Earnings Forecast

Key Fulcrum Therapeutics Financial Ratios

  • The Research & Development expenses have been 2,559.75% of Revenue.
  • The Net Earning history of FULC is -3,470.05% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 4 years.

Fulcrum Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: FULC
CUSIP: 359616
Website: fulcrumtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FULC Technical Analysis vs Fundamental Analysis

Sell
41
Fulcrum Therapeutics (FULC) is a Sell

Is Fulcrum Therapeutics a Buy or a Sell?